.
.
.
Analytical Services for Generic Drug Development
At ResolveMass Laboratories Inc., our Analytical Services for Generic Drug Development are designed to support pharmaceutical companies in achieving regulatory compliance, product quality, and faster market entry. With deep scientific expertise and advanced instrumentation, we deliver accurate, reliable, and regulatory-aligned analytical solutions tailored to generic formulations.
Comprehensive Analytical Support for Generic Drug Development
Our Analytical Services for Generic Drug Development cover the full lifecycle of pharmaceutical products—from early-stage development to post-market support. We specialize in conducting method validation, impurity profiling, and stability testing, ensuring that every product meets stringent global regulatory standards. Our scientific team combines hands-on laboratory experience with a strong understanding of guidelines from authorities such as ICH, USP, and FDA, delivering results you can trust.
Our Core Analytical Capabilities
Method Development & Validation
We design and validate robust analytical methods tailored to your formulation. Our validation processes ensure accuracy, precision, specificity, linearity, and reproducibility in accordance with ICH Q2(R2) guidelines.
Impurity Profiling
We conduct comprehensive impurity profiling to identify, quantify, and control process-related and degradation impurities. Our advanced techniques ensure compliance with regulatory thresholds and safety requirements.
Stability Testing
Our stability studies evaluate product performance under various environmental conditions. We generate reliable data to support shelf-life determination and regulatory submissions.
Advanced & Specialized Testing Capabilities
ResolveMass Laboratories Inc. offers specialized analytical testing to address emerging regulatory concerns and complex formulations. Our laboratories are equipped to handle highly sensitive and technically demanding studies.
- Nitrosamine impurity testing with ultra-sensitive detection methods
- Extractables and leachables analysis
- Residual solvent testing (ICH Q3C compliance)
- Elemental impurity analysis (ICH Q3D)
- Forced degradation studies
- Dissolution method development and testing
Why Choose ResolveMass Laboratories Inc.?
Our reputation is built on scientific rigor, regulatory expertise, and a commitment to data integrity. We bring deep analytical experience in supporting generic drug manufacturers globally.
- Experienced analytical scientists with deep domain expertise
- Compliance with global regulatory standards (ICH, FDA, USP)
- Advanced instrumentation and validated methodologies
- Transparent reporting and data integrity assurance
- Customized solutions tailored to each client’s needs
Our Analytical Workflow
- Understanding client requirements and regulatory goals
- Method development and feasibility assessment
- Method validation and optimization
- Routine analytical testing and documentation
- Regulatory submission support
Industries We Support
Our Analytical Services for Generic Drug Development are trusted by pharmaceutical companies, contract development organizations, and research institutions worldwide. We support oral solids, injectables, topical formulations, and complex generics.
Looking for End-to-End Generic Drug Development Support? 👉 Explore Our Generic Drug Development CDMO Services
Conclusion
Choosing the right partner for Analytical Services for Generic Drug Development is essential for ensuring product quality, regulatory compliance, and timely approvals. At ResolveMass Laboratories Inc., we combine scientific expertise, advanced technology, and a commitment to excellence to support your success at every stage of development.
Ready to accelerate your generic drug development?
👉 Contact our experts today
Frequently Asked Questions (FAQs)
Analytical services involve a range of laboratory testing activities that verify the quality and consistency of a drug product. These include developing and validating test methods, identifying impurities, and conducting stability studies. Such services ensure that the drug meets regulatory standards before reaching the market.
Method validation confirms that a testing procedure consistently produces accurate and dependable results. It evaluates parameters like precision, specificity, and reproducibility under defined conditions. This process is essential to demonstrate that the method is suitable for its intended analytical purpose.
Impurity profiling helps detect and measure unwanted substances that may arise during manufacturing or storage. Understanding these impurities is important to ensure patient safety and maintain drug effectiveness. Regulatory agencies also require detailed impurity data as part of approval submissions.
Stability testing assesses how a drug product behaves over time when exposed to different environmental conditions. It helps determine shelf life, packaging requirements, and proper storage instructions. Reliable stability data is necessary for regulatory approval and product labeling.
Accurate analytical data is a key component of any regulatory submission for generic drugs. It provides evidence that the product meets required quality and safety standards. Well-documented results help streamline the review process and reduce the chances of delays.
Modern laboratories use advanced instruments such as chromatography systems and mass spectrometry for precise analysis. These tools allow scientists to detect even trace levels of compounds. The use of reliable technology ensures high-quality and reproducible results.
Analytical testing is performed according to internationally recognized guidelines to ensure consistency and reliability. These include recommendations from regulatory bodies that define acceptable limits and testing procedures. Adhering to these standards ensures global acceptance of the results.
Reference:
- Raney, S. G., Krishnan, V., Dick, J., & others. (2024). Application of advanced modeling approaches supporting generic product development under GDUFA for fiscal year 2023. The AAPS Journal. https://doi.org/10.1208/s12248-024-00924-8
- U.S. Food and Drug Administration. (2024, September 24). Advancing generic drug development: Translating science to approval. https://www.fda.gov/drugs/news-events-human-drugs/advancing-generic-drug-development-translating-science-approval-2024-09242024
- Joshi, S. S., Shetty, Y. C., & Karande, S. (2019). Generic drugs – The Indian scenario. Journal of Postgraduate Medicine, 65(2), 67–69. https://doi.org/10.4103/jpgm.JPGM_420_18
- Lionberger, R. A. (2008). FDA critical path initiatives: Opportunities for generic drug development. The AAPS Journal, 10(1), 103–109. https://doi.org/10.1208/s12248-008-9010-2